Q&A by unknown
What was the genesis of the Michelson 
program?
GILBREATH: When Michelson 
got interested in how to keep 
so many pets from being 
euthanized in shelters, he real-
ized that affordability and 
accessibility of spay and neuter were an 
issue. He started thinking that technology 
has got to have a solution to this that is non-
surgical, affordable, and easy to deploy in a 
field setting. 
JOHNSTON: There has never 
been such an amount of mon-
ey available to study dog and 
cat reproduction. Our program 
is trying to get the word out 
to not only scientists who have worked in 
the field of dog and cat reproduction, 
but also people who work on basic cellular 
mechanisms, people who work in human 
reproduction. To date we’ve approved 
about 15 proposals. 
Million-Dollar Baby
FOUNDATION BRINGS BIG BUCKS TO THE 
SEARCH FOR A NONSURGICAL SPAY/NEUTER SOLUTION
t can’t buy you love, and it may be the root of all evil, but 
money can get things done. It might, in fact, spur a solution 
to pet overpopulation and the untimely deaths of millions of 
cats and dogs around the world.
That’s the hope of the Found Animals Foundation, a Los 
Angeles–based nonprofit founded by billionaire spinal surgeon 
Gary Michelson that focuses on ending pet homelessness. In 2008, 
the foundation announced an eye-popping brass ring: $25 million 
to the first entity to develop a low-cost, single-dose, nonsurgical 
method for permanently sterilizing cats and dogs. The Michelson 
Prize and Grants in Reproductive Biology made another $50 mil-
lion available for related research.
The stakes are high—but not just for researchers. While con-
ventional spay/neuter surgeries have had a tremendous impact on 
reducing euthanasia rates in the U.S., 3 to 4 million cats and dogs 
are still put down for lack of homes. In many areas, feral cats are 
still caught in an endless cycle of breeding and competition for 
food. A sterilant that can be deployed in the field and that doesn’t 
require hours or days of recovery time could enable local animal 
groups to break that cycle with less money and fewer volunteers. 
In developing nations, where hundreds of millions of street dogs 
eke out an existence, the lifesaving possibilities are even greater. 
While traditional trap-neuter-return programs can stabilize popu-
lations when practiced on a large scale, local governments too 
often rely on stopgap, inhumane control methods, such as poison-
ing, drowning, or electrocution. 
Found Animals executive director Aimee Gilbreath believes a 
nonsurgical sterilant—whether an injectable, a pill, or a medical 
device—will be a reality in this decade. Even a product that works 
on only one species could still be brought to market with great 
benefits, she notes. In this edited interview with The HSUS’s 
James Hettinger, Gilbreath and Shirley Johnston, a veterinarian 
and former researcher who is also with Found Animals, discuss the 
progress to date—and the promise for the future.
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TRICKING THE IMMUNE SYSTEM  Michael Munks heard 
about the Michelson Prize and Grants not through a sci-
ence journal or a grants website, but while watching 
Saturday Night Live. “They were making a joke about how 
the cats and dogs had put together [$80] million to hire 
a hit man to take out Gary Michelson,” says the immu-
nologist with National Jewish Health in Denver.
Munks was more intrigued than amused. In late 2009, 
he received a $733,000 grant for a study involving immu-
nocontraception: fooling the immune system into deac-
tivating part of the reproductive system. He’ll use the 
money to research whether a herpes virus can lead to a 
dog and cat sterilant.
UNINTENDED BENEFITS Information about the 
Michelson project “stuck someplace at the back of my 
head,” says Crinetics Pharmaceuticals’ Scott Struthers. 
Eventually, Struthers realized there could be a connec-
tion with his firm’s work on an anti-ovarian cancer drug, 
which can render women sterile. While sterility wasn’t an 
intended side effect for its human applications, Struthers 
wondered about the possibilities for dogs and cats. He 
received $1.4 million to research the possibilities.
In a time when funding is tight, Struthers credits the 
Michelson program with catching the eyes of researchers 
“who are normally just thinking about humans, and mak-
ing them think about what they can do for our pets.”
SEEKING A “MAGIC BULLET”  Normally, William Ja uses 
fruit flies to study human aging, nutrition, and disease. 
Now, with a $206,000 Michelson grant, the assistant pro-
fessor at Scripps Research Institute in Jupiter, Fla., is 
working on a spay/neuter “magic bullet” (technically 
known as a toxin-ligand conjugate) that would target 
crucial reproductive cells in cats and dogs.
It’s a daunting task, but Ja is confident that someone 
will devise at least a partial solution. “I think it should be 
doable, given the examples of sterility that occur in 
nature,” he says. “… And certainly this giant load of cash 
will help the field greatly.” 
The Quest for the 
Holy Grail
A look at three researchers 
vying for the Michelson Prize
A nonsurgical sterilant could make a world of difference for the hundreds of millions of 
stray dogs around the globe. Too often, local governments deal with overpopulation 
through poisoning, electrocution, and shooting.
How affordable do you think the sterilant will be? 
JOHNSTON: One of the requirements for winning the prize is that it has 
a reasonable manufacturing cost. We hope that it will be in the neighbor-
hood of $5 to $10 [per dose] when manufactured on a large scale. 
Are the obstacles scientific problems or a lack of research funding? 
GILBREATH: It’s probably a combination. Nonsurgical products for 
humans are out there. I have no doubt that it is technologically possible 
to do it for pets. I have to think that a lot of it has been technology and 
funding to really motivate people to apply cutting-edge technology to 
the issue.
JOHNSTON: It’s not easy to completely disable the reproductive sys-
tems. I’ve worked in dog and cat reproduction for nearly 40 years now, 
and people have done good research in trying to find safe contraceptive 
agents. But in my career at universities, you would scramble to get a 
$10,000 to $50,000 grant, and now we are making available a quarter of 
a million dollars a year for three to four years. We’ve really had some quite 
brilliant proposals come in that we think may be able to solve this 
challenge.
Do you think you’ll find what you’re looking for?
JOHNSTON: I’m really optimistic. Initially, I thought it was like saying 
to somebody, “Oh, we’ll give you $25 million to turn lead into gold.” But I 
have since come to recognize that in the last 10 to 15 years, science has 
advanced on so many fronts that now I really do believe we’re going to 
award this prize. 
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